Revision: Nov. 13, 2025, 9:23 a.m.
Rep. Chourasia, Hills. 11
October 28, 2025
2025-3059h
05/07
Amendment to HB 648-FN
Amend RSA 415:6-e, III(a) as inserted by section 1 of the bill by replacing it with the following:
(a) Coverage under this paragraph shall be provided without regard to the form of treatment. Insulin utilization, frequency of administration of insulin, or frequency of blood glucose testing shall not be a requirement for coverage of blood glucose monitoring or CGMS. Preferred providers or formularies shall include at least 2 of each kind of device. An endocrinology referral or prescription shall be required. Prior authorization shall be required.
Amend RSA 415:18-f, III(a) as inserted by section 2 of the bill by replacing it with the following:
(a) Coverage under this paragraph shall be provided without regard to the form of treatment. Insulin utilization, frequency of administration of insulin, or frequency of blood glucose testing shall not be a requirement for coverage of blood glucose monitoring or CGMS. Preferred providers or formularies shall include at least 2 of each kind of device. An endocrinology referral or prescription shall be required. Prior authorization shall be required.
Amend RSA 420-A:17-a, III(a) as inserted by section 3 of the bill by replacing it with the following:
(a) Coverage under this paragraph shall be provided without regard to the form of treatment. Insulin utilization, frequency of administration of insulin, or frequency of blood glucose testing shall not be a requirement for coverage of blood glucose monitoring or CGMS. Preferred providers or formularies shall include at least 2 of each kind of device. An endocrinology referral or prescription shall be required. Prior authorization shall be required.
Amend RSA 420-B:8-k, III(a) as inserted by section 4 of the bill by replacing it with the following:
(a) Coverage under this paragraph shall be provided without regard to the form of treatment. Insulin utilization, frequency of administration of insulin, or frequency of blood glucose testing shall not be a requirement for coverage of blood glucose monitoring or CGMS. Preferred providers or formularies shall include at least 2 of each kind of device. An endocrinology referral or prescription shall be required. Prior authorization shall be required.